Vuno Inc.

KOSDAQ:A338220 Stock Report

Market Cap: ₩95.4b

Vuno Valuation

Is A338220 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A338220 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate A338220's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate A338220's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A338220?

Key metric: As A338220 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A338220. This is calculated by dividing A338220's market cap by their current revenue.
What is A338220's PS Ratio?
PS Ratio2.8x
Sales₩33.36b
Market Cap₩95.35b

Price to Sales Ratio vs Peers

How does A338220's PS Ratio compare to its peers?

The above table shows the PS ratio for A338220 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.5x
A226400 OSTEONIC
1.9xn/a₩87.8b
A156100 L&K Biomed
1.6xn/a₩87.1b
A056090 CG MedTechLtd
1.9xn/a₩89.2b
A035610 Solborn
0.8xn/a₩100.7b
A338220 Vuno
2.8xn/a₩95.4b

Price-To-Sales vs Peers: A338220 is expensive based on its Price-To-Sales Ratio (2.8x) compared to the peer average (1.5x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does A338220's PS Ratio compare vs other companies in the KR Medical Equipment Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
A008490 Suheung
0.3xn/aUS$151.56m
A122310 Genoray
0.4xn/aUS$29.78m
A261200 DENTISLtd
0.3xn/aUS$27.21m
A083550 KM
0.2xn/aUS$20.09m
A338220 2.8xIndustry Avg. 1.8xNo. of Companies16PS01.63.24.86.48+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A338220 is expensive based on its Price-To-Sales Ratio (2.8x) compared to the KR Medical Equipment industry average (1.8x).

Price to Sales Ratio vs Fair Ratio

What is A338220's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A338220 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A338220's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

₩28k
Fair Value
76.4% undervalued intrinsic discount
0
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/30 14:35
End of Day Share Price 2026/07/30 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vuno Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ji-Eun KimDB Financial Investment Co. Ltd.